Cell Death Dis:HOXA4可能作为肺癌抑癌基因

2018-05-01 QiaoQiao 转化医学网

肺癌是全球癌症相关死亡的主要原因。 最常见的肺癌类型是非小细胞肺癌(NSCLC),约占肺癌病例的85%。大多数肺癌的总生存率相对较低,主要原因是缺乏明显的初始症状和有效的治疗手段。

肺癌是全球癌症相关死亡的主要原因。 最常见的肺癌类型是非小细胞肺癌NSCLC),约占肺癌病例的85%。大多数肺癌的总生存率相对较低,主要原因是缺乏明显的初始症状和有效的治疗手段。

已有研究确定了几种肺癌发生的相关通路,其中包括表皮生长因子受体(EGFR),p16INK4 / Cyclin D1 / Rb和Wnt信号通路。 针对这些途径的治疗也为肺癌的治疗提供了广阔的前景。

HOXA4在癌症进展中的功能很少被研究,除了它在抑制卵巢癌细胞系迁移中的作用。研究发现HOXA4在结直肠癌和上皮性卵巢癌中过表达,而且通过β1整合素17抑制卵巢癌细胞系的迁移。HOXA4属于同源盒(HOX)基因家族,其特征在于存在编码高度保守的同源域的183个碱基对的DNA序列(同源框)。HOX基因编码转录因子,通过与各种靶基因的启动子结合并调节表达来控制细胞分化和胚胎发育,以往的研究已经证实了HOXA5,HOXA10,HOXB3,HOXB4和HOXC6等HOX基因家族的其他成员与正常组织相比在肺癌组织中过表达。目前,尽管已经知道Hoxa4基因参与胚胎发育期间小鼠肺的模式化,但对HOXA4在肺癌的表达和生物学功能知之甚少 。

近日,《Cell Death Dis》上一篇名为“HOXA4, down-regulated in lung cancer, inhibits the growth, motility and invasion of lung cancer cells ”的文章中,研究人员发现HOXA4的表达与细胞周期,转移和Wnt信号通路呈负相关。与非癌组织相比,肺癌组织中HOXA4的表达下调,进一步研究发现其降低与肺癌的肿瘤大小,TNM分期,淋巴结转移和不良预后相关,因此可能成为肺癌的潜在治疗靶点,而且它的表达水平也可作为肺癌的一种新型预后指标。这是HOXA4可能作为肺癌抑癌基因的首例报道。

在该研究中,与非癌组织相比,肺癌组织中HOXA4的表达下调。

研究人员使用从癌症基因组图谱项目下载的数据集分析人类肺癌组织中的HOXA4表达。


图a显示,与正常肺组织(n = 58)相比,肺癌组织(n = 488)中HOXA4表达水平降低(4.81±0.06比6.82±0.10,P <0.0001)。 此外,进行定量逆转录聚合酶链反应(qRT-PCR)分析以检查HOXA4在医院患者肺癌样本和相邻正常组织中的表达情况(图b),发现HOXA4 mRNA在肿瘤组织(n = 100)中的表达低于正常肺组织(n = 40)(2.01±0.06比3.49±0.21,P <0.0001)。研究人员还将100例肺癌患者分为两组:HOXA4高表达组和HOXA4低表达组。 通过Fisher精确检验分析,发现HOXA4在肺癌中的表达与肿瘤大小(P = 0.0262),TNM分期(P = 0.0088)和淋巴结转移(P = 0.0076)显着相关。 不过,HOXA4在肺癌中的表达与年龄(P = 0.6845),性别(P = 0.4230)或吸烟状态(P = 0.5269)无关。然后通过Kaplan-Meier分析来评估HOXA4表达与手术后肺癌患者结局之间的关系。 总生存(OS)曲线(图c)显示,HOXA4表达水平较低的患者OS较差(P <0.01)。

这些数据足以证明HOXA4在肺癌诊断中的临床意义,HOXA4表达水平可能是肺癌的一种新型预后指标。

而后研究人员进行基因富集分析(GSEA)以评估TCGA肺癌样品中与HOXA4表达相关的途径,结果显示HOXA4的表达与细胞周期,转移和Wnt信号通路呈负相关。


GSEA分析显示HOXA4与TCGA肺癌样品中的细胞周期(a),转移(b)和Wnt信号传导途径(c)负相关

Wnt信号通路在癌症的发生发展和预后中发挥重要作用。如HOXA5抑制结肠癌细胞系中的Wnt信号活性,HOXA9和HOXA10激活人CD34 +脐带血细胞中的Wnt信号活性。在这里,TCGA数据集中的GSEA显示HOXA4表达与Wnt信号传导途径呈负相关,HOXA4的异位表达导致Wnt通路的下游效应蛋白(β-连环蛋白,细胞周期蛋白D1,c-Myc和存活蛋白)的蛋白水平明显降低,因此,肺癌患者的β-连环蛋白表达降低可作为一个不良预后因素。

HOXA4过表达增加GSK3β蛋白和mRNA水平。

研究发现HOXA4过表达显着增强了GSK3β的相对荧光素酶活性和GSK3β启动子的富集,但HOXA4敲低显着降低了GSK3β的表达。 因此,研究人员推测HOXA4可能通过促进其转录,然后抑制Wnt信号传导而增加GSK3β的表达。此外,通过LiCl抑制GSK3β可以消除HOXA4介导的细胞生长,迁移和侵袭的抑制。

另外, HOXA4在异种移植肿瘤中的过表达也降低了肿瘤生长和Wnt信号传导。

总之,HOXA4的下调与肺癌预后不良有关,是一种潜在的肺癌抑癌基因。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1870605, encodeId=58b818e0605f2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jan 22 04:58:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012659, encodeId=92a42012659e1, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun May 27 15:58:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1640658, encodeId=407a16406582a, content=<a href='/topic/show?id=fd575494e5e' target=_blank style='color:#2F92EE;'>#抑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54947, encryptionId=fd575494e5e, topicName=抑癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f822706827, createdName=jingyanzhu715_39486108, createdTime=Tue Oct 09 19:58:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315970, encodeId=81603159e01c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIxvMP6OXzUiaGH5MkDQlW0hczROZxec1gZjfZ52EtN6aG9t0uDZq2A5xmf9FWMa4tZib4qoYnledFg/132, createdBy=9d6c2167401, createdName=hanmeijinxiu, createdTime=Thu May 17 10:58:44 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960874, encodeId=c0b719608e4af, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jul 27 01:58:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323244, encodeId=3f28132324484, content=<a href='/topic/show?id=9934549500e' target=_blank style='color:#2F92EE;'>#抑癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54950, encryptionId=9934549500e, topicName=抑癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373931, encodeId=05b913e3931b6, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531423, encodeId=cb091531423f0, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311520, encodeId=8f5b31152003, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 03 06:52:22 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311287, encodeId=e95331128efc, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed May 02 11:26:49 CST 2018, time=2018-05-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1870605, encodeId=58b818e0605f2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jan 22 04:58:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012659, encodeId=92a42012659e1, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun May 27 15:58:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1640658, encodeId=407a16406582a, content=<a href='/topic/show?id=fd575494e5e' target=_blank style='color:#2F92EE;'>#抑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54947, encryptionId=fd575494e5e, topicName=抑癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f822706827, createdName=jingyanzhu715_39486108, createdTime=Tue Oct 09 19:58:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315970, encodeId=81603159e01c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIxvMP6OXzUiaGH5MkDQlW0hczROZxec1gZjfZ52EtN6aG9t0uDZq2A5xmf9FWMa4tZib4qoYnledFg/132, createdBy=9d6c2167401, createdName=hanmeijinxiu, createdTime=Thu May 17 10:58:44 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960874, encodeId=c0b719608e4af, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jul 27 01:58:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323244, encodeId=3f28132324484, content=<a href='/topic/show?id=9934549500e' target=_blank style='color:#2F92EE;'>#抑癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54950, encryptionId=9934549500e, topicName=抑癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373931, encodeId=05b913e3931b6, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531423, encodeId=cb091531423f0, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311520, encodeId=8f5b31152003, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 03 06:52:22 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311287, encodeId=e95331128efc, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed May 02 11:26:49 CST 2018, time=2018-05-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1870605, encodeId=58b818e0605f2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jan 22 04:58:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012659, encodeId=92a42012659e1, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun May 27 15:58:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1640658, encodeId=407a16406582a, content=<a href='/topic/show?id=fd575494e5e' target=_blank style='color:#2F92EE;'>#抑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54947, encryptionId=fd575494e5e, topicName=抑癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f822706827, createdName=jingyanzhu715_39486108, createdTime=Tue Oct 09 19:58:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315970, encodeId=81603159e01c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIxvMP6OXzUiaGH5MkDQlW0hczROZxec1gZjfZ52EtN6aG9t0uDZq2A5xmf9FWMa4tZib4qoYnledFg/132, createdBy=9d6c2167401, createdName=hanmeijinxiu, createdTime=Thu May 17 10:58:44 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960874, encodeId=c0b719608e4af, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jul 27 01:58:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323244, encodeId=3f28132324484, content=<a href='/topic/show?id=9934549500e' target=_blank style='color:#2F92EE;'>#抑癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54950, encryptionId=9934549500e, topicName=抑癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373931, encodeId=05b913e3931b6, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531423, encodeId=cb091531423f0, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311520, encodeId=8f5b31152003, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 03 06:52:22 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311287, encodeId=e95331128efc, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed May 02 11:26:49 CST 2018, time=2018-05-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1870605, encodeId=58b818e0605f2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jan 22 04:58:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012659, encodeId=92a42012659e1, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun May 27 15:58:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1640658, encodeId=407a16406582a, content=<a href='/topic/show?id=fd575494e5e' target=_blank style='color:#2F92EE;'>#抑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54947, encryptionId=fd575494e5e, topicName=抑癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f822706827, createdName=jingyanzhu715_39486108, createdTime=Tue Oct 09 19:58:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315970, encodeId=81603159e01c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIxvMP6OXzUiaGH5MkDQlW0hczROZxec1gZjfZ52EtN6aG9t0uDZq2A5xmf9FWMa4tZib4qoYnledFg/132, createdBy=9d6c2167401, createdName=hanmeijinxiu, createdTime=Thu May 17 10:58:44 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960874, encodeId=c0b719608e4af, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jul 27 01:58:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323244, encodeId=3f28132324484, content=<a href='/topic/show?id=9934549500e' target=_blank style='color:#2F92EE;'>#抑癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54950, encryptionId=9934549500e, topicName=抑癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373931, encodeId=05b913e3931b6, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531423, encodeId=cb091531423f0, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311520, encodeId=8f5b31152003, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 03 06:52:22 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311287, encodeId=e95331128efc, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed May 02 11:26:49 CST 2018, time=2018-05-02, status=1, ipAttribution=)]
    2018-05-17 hanmeijinxiu

    学习了.谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1870605, encodeId=58b818e0605f2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jan 22 04:58:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012659, encodeId=92a42012659e1, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun May 27 15:58:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1640658, encodeId=407a16406582a, content=<a href='/topic/show?id=fd575494e5e' target=_blank style='color:#2F92EE;'>#抑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54947, encryptionId=fd575494e5e, topicName=抑癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f822706827, createdName=jingyanzhu715_39486108, createdTime=Tue Oct 09 19:58:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315970, encodeId=81603159e01c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIxvMP6OXzUiaGH5MkDQlW0hczROZxec1gZjfZ52EtN6aG9t0uDZq2A5xmf9FWMa4tZib4qoYnledFg/132, createdBy=9d6c2167401, createdName=hanmeijinxiu, createdTime=Thu May 17 10:58:44 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960874, encodeId=c0b719608e4af, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jul 27 01:58:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323244, encodeId=3f28132324484, content=<a href='/topic/show?id=9934549500e' target=_blank style='color:#2F92EE;'>#抑癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54950, encryptionId=9934549500e, topicName=抑癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373931, encodeId=05b913e3931b6, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531423, encodeId=cb091531423f0, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311520, encodeId=8f5b31152003, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 03 06:52:22 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311287, encodeId=e95331128efc, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed May 02 11:26:49 CST 2018, time=2018-05-02, status=1, ipAttribution=)]
    2018-07-27 维他命
  6. [GetPortalCommentsPageByObjectIdResponse(id=1870605, encodeId=58b818e0605f2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jan 22 04:58:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012659, encodeId=92a42012659e1, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun May 27 15:58:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1640658, encodeId=407a16406582a, content=<a href='/topic/show?id=fd575494e5e' target=_blank style='color:#2F92EE;'>#抑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54947, encryptionId=fd575494e5e, topicName=抑癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f822706827, createdName=jingyanzhu715_39486108, createdTime=Tue Oct 09 19:58:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315970, encodeId=81603159e01c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIxvMP6OXzUiaGH5MkDQlW0hczROZxec1gZjfZ52EtN6aG9t0uDZq2A5xmf9FWMa4tZib4qoYnledFg/132, createdBy=9d6c2167401, createdName=hanmeijinxiu, createdTime=Thu May 17 10:58:44 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960874, encodeId=c0b719608e4af, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jul 27 01:58:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323244, encodeId=3f28132324484, content=<a href='/topic/show?id=9934549500e' target=_blank style='color:#2F92EE;'>#抑癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54950, encryptionId=9934549500e, topicName=抑癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373931, encodeId=05b913e3931b6, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531423, encodeId=cb091531423f0, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311520, encodeId=8f5b31152003, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 03 06:52:22 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311287, encodeId=e95331128efc, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed May 02 11:26:49 CST 2018, time=2018-05-02, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1870605, encodeId=58b818e0605f2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jan 22 04:58:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012659, encodeId=92a42012659e1, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun May 27 15:58:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1640658, encodeId=407a16406582a, content=<a href='/topic/show?id=fd575494e5e' target=_blank style='color:#2F92EE;'>#抑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54947, encryptionId=fd575494e5e, topicName=抑癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f822706827, createdName=jingyanzhu715_39486108, createdTime=Tue Oct 09 19:58:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315970, encodeId=81603159e01c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIxvMP6OXzUiaGH5MkDQlW0hczROZxec1gZjfZ52EtN6aG9t0uDZq2A5xmf9FWMa4tZib4qoYnledFg/132, createdBy=9d6c2167401, createdName=hanmeijinxiu, createdTime=Thu May 17 10:58:44 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960874, encodeId=c0b719608e4af, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jul 27 01:58:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323244, encodeId=3f28132324484, content=<a href='/topic/show?id=9934549500e' target=_blank style='color:#2F92EE;'>#抑癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54950, encryptionId=9934549500e, topicName=抑癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373931, encodeId=05b913e3931b6, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531423, encodeId=cb091531423f0, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311520, encodeId=8f5b31152003, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 03 06:52:22 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311287, encodeId=e95331128efc, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed May 02 11:26:49 CST 2018, time=2018-05-02, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1870605, encodeId=58b818e0605f2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jan 22 04:58:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012659, encodeId=92a42012659e1, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun May 27 15:58:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1640658, encodeId=407a16406582a, content=<a href='/topic/show?id=fd575494e5e' target=_blank style='color:#2F92EE;'>#抑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54947, encryptionId=fd575494e5e, topicName=抑癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f822706827, createdName=jingyanzhu715_39486108, createdTime=Tue Oct 09 19:58:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315970, encodeId=81603159e01c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIxvMP6OXzUiaGH5MkDQlW0hczROZxec1gZjfZ52EtN6aG9t0uDZq2A5xmf9FWMa4tZib4qoYnledFg/132, createdBy=9d6c2167401, createdName=hanmeijinxiu, createdTime=Thu May 17 10:58:44 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960874, encodeId=c0b719608e4af, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jul 27 01:58:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323244, encodeId=3f28132324484, content=<a href='/topic/show?id=9934549500e' target=_blank style='color:#2F92EE;'>#抑癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54950, encryptionId=9934549500e, topicName=抑癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373931, encodeId=05b913e3931b6, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531423, encodeId=cb091531423f0, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311520, encodeId=8f5b31152003, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 03 06:52:22 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311287, encodeId=e95331128efc, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed May 02 11:26:49 CST 2018, time=2018-05-02, status=1, ipAttribution=)]
    2018-05-03 cy0328
  9. [GetPortalCommentsPageByObjectIdResponse(id=1870605, encodeId=58b818e0605f2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jan 22 04:58:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012659, encodeId=92a42012659e1, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun May 27 15:58:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1640658, encodeId=407a16406582a, content=<a href='/topic/show?id=fd575494e5e' target=_blank style='color:#2F92EE;'>#抑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54947, encryptionId=fd575494e5e, topicName=抑癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f822706827, createdName=jingyanzhu715_39486108, createdTime=Tue Oct 09 19:58:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315970, encodeId=81603159e01c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIxvMP6OXzUiaGH5MkDQlW0hczROZxec1gZjfZ52EtN6aG9t0uDZq2A5xmf9FWMa4tZib4qoYnledFg/132, createdBy=9d6c2167401, createdName=hanmeijinxiu, createdTime=Thu May 17 10:58:44 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960874, encodeId=c0b719608e4af, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jul 27 01:58:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323244, encodeId=3f28132324484, content=<a href='/topic/show?id=9934549500e' target=_blank style='color:#2F92EE;'>#抑癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54950, encryptionId=9934549500e, topicName=抑癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373931, encodeId=05b913e3931b6, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531423, encodeId=cb091531423f0, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311520, encodeId=8f5b31152003, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 03 06:52:22 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311287, encodeId=e95331128efc, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed May 02 11:26:49 CST 2018, time=2018-05-02, status=1, ipAttribution=)]
    2018-05-03 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1870605, encodeId=58b818e0605f2, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Jan 22 04:58:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012659, encodeId=92a42012659e1, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun May 27 15:58:00 CST 2018, time=2018-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1640658, encodeId=407a16406582a, content=<a href='/topic/show?id=fd575494e5e' target=_blank style='color:#2F92EE;'>#抑癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54947, encryptionId=fd575494e5e, topicName=抑癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=35f822706827, createdName=jingyanzhu715_39486108, createdTime=Tue Oct 09 19:58:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315970, encodeId=81603159e01c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIxvMP6OXzUiaGH5MkDQlW0hczROZxec1gZjfZ52EtN6aG9t0uDZq2A5xmf9FWMa4tZib4qoYnledFg/132, createdBy=9d6c2167401, createdName=hanmeijinxiu, createdTime=Thu May 17 10:58:44 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1960874, encodeId=c0b719608e4af, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Jul 27 01:58:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323244, encodeId=3f28132324484, content=<a href='/topic/show?id=9934549500e' target=_blank style='color:#2F92EE;'>#抑癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54950, encryptionId=9934549500e, topicName=抑癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373931, encodeId=05b913e3931b6, content=<a href='/topic/show?id=3644e1286f1' target=_blank style='color:#2F92EE;'>#癌基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71286, encryptionId=3644e1286f1, topicName=癌基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee7b365, createdName=zhucaizhong7766, createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531423, encodeId=cb091531423f0, content=<a href='/topic/show?id=770e5e9457' target=_blank style='color:#2F92EE;'>#Death#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5794, encryptionId=770e5e9457, topicName=Death)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32e312278742, createdName=cy0328, createdTime=Thu May 03 12:58:00 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311520, encodeId=8f5b31152003, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu May 03 06:52:22 CST 2018, time=2018-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=311287, encodeId=e95331128efc, content=学习学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Wed May 02 11:26:49 CST 2018, time=2018-05-02, status=1, ipAttribution=)]
    2018-05-02 kafei

    学习学习谢谢分享

    0

相关资讯

肺癌微波消融治疗经验分享

在世界范围内,肺癌的发病率和死亡率居癌症之首,全球每年发病约250万例,每年有超过160万人死于肺癌。

2018 CHEST指南:肺癌筛查

再过去的几年里,低剂量胸部CT检查已经成为美国肺癌筛查的一种标准的措施。本文基于低剂量胸部CT筛查的风险,获益以及适应证更新的相关证据,并依据最新证据提出了肺癌筛查的建议。

安罗替尼III期研究ALTER0303数据写入《2018版CSCO肺癌指南》

4月21日,2018年CSCO指南大会在南京顺利召开。肺癌作为近年来进展最快的瘤种之一,在新版《CSCO原发性肺癌诊疗指南》上,再次更新了众多研究进展。值得一提的是,由我国自主研发的国家1.1类新药,多靶点酪氨酸激酶抑制剂安罗替尼的III期研究ALTER0303数据写入《2018版CSCO原发性肺癌诊疗指南》。安罗替尼即将上市,有望填补我国晚期NSCLC三线治疗的空白,造福中国患者。

CLIN CANCER RES:通过循环肿瘤DNA早期评估肺癌免疫治疗反应

通常通过连续的影像学检测决定需要继续还是中断免疫检查点抑制治疗。但是,由于肿瘤缩小缓慢或由于炎症反应反而出现增大时,免疫治疗反应评估难度较大。CLIN CANCER RES近期发表了一篇文章,研究监测循环肿瘤DNA(ctDNA)水平改变是否可以早期进行免疫治疗效果评估。

Cell:继构建全球很大肺癌细胞库后,他们又找到170种治疗肺癌的潜在药物

“从超20万种化合物中筛选出170种潜在的抗肺癌药物”——这是美国德克萨斯大学西南医学中心的科学家们最新取得的成果。继构建了全球最大的肺癌细胞库之后,他们利用这一资源,绘制出肺癌遗传突变与潜在药物之间的关联。

AZ的肺癌药物Tagrisso在欧洲获准作为一线用药

欧洲的监管顾问支持阿斯利康公司的肺癌药物Tagrisso作为一线用药的批准。欧洲药品管理局人用药品委员会(CHMP)建议扩大该药品的标签,以包括表皮生长因子受体(EGFR)突变的成人局部晚期或转移性非小细胞肺癌(NSCLC)的成人一线治疗。该研究的首席医疗官Sean Bohen指出:"该积极的建议承认Tagrisso的osimertinib具有欧洲EGFR突变NSCLC患者的一线治疗新标准的潜力。